Introduction of The OIS Index at OIS@AAO 2016.
Presenter:
Michael Lachman, Founder - EyeQ Research
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
2. October 13, 2016 ■ Page 1
Stock Market Indices
US Broad Market Indices
Dow Jones Industrial Average
S&P-500
Russell 3000
International Market Indices
Nikkei 225 (Tokyo), FTSE 100 (London), DAX Index (Frankfurt)
Market Sector Indices
Dow Jones Transportation and Utility Averages
NASDAQ Biotechnology Index
3. October 13, 2016 ■ Page 2
Introducing the OIS Index
October 1, 2016
1,000.00
4. October 13, 2016 ■ Page 3
OIS Index Methodology
Mid-Cap and Small-Cap Ophthalmic Companies
Publicly Traded
≥ 50% Ophthalmology
Initial Composition: 70% Biopharma, 30% Ophthalmic Device
Market Cap Weighted, with Limits
Largest Companies Capped at 10% of Total Index Value
Others Capped at 8% and 6%
Updated and Rebalanced Quarterly
IPOs, Acquisitions, Share Counts
30 - Eleven = 29
6. October 13, 2016 ■ Page 5
OIS Index – Six Month Performance
April 1 – October 1, 2016 OIS Index +22%
Total US Market +6%
US Medical
Devices + 19%
NASDAQ
Biotechnology
Index + 11%
Total US market based on Russell 3000 Index (^RUA)
US medical devices based on iShares US Medical Devices ETF (IHI)
Equity valuations from MarketXLS
7. October 13, 2016 ■ Page 6
OIS Index – Key Drivers of Performance
April 1 – October 1, 2016
Aerie Pharmaceuticals
Glaukos
Spark Therapeutics
Clearside BioMedical
Omeros
AGTC
Molecular Partners